Operationalizing Bispecifics in Multiple Myeloma

In this special episode of Managed Care Cast, the executive editor of The American Journal of Managed Care^®, Mary Caffrey, speaks with Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology's Nashville-Midtown Center for Blood Cancers, about the use of bispecific antibodies to treat patients with multiple myeloma, the importance of caregivers for this regimen, how the entire staff plays a role, the common adverse events patients need to be looking out for, and more.

Our conversation keys on themes from the recent article, “Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination,”¹ led by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, who is clinical pharmacy manager for the University of Kansas Health System. Sandahl was a coauthor on the paper and joins us for the first part of today’s podcast.

For the second part, Byrne, who was previously with Vanderbilt University Medical Center, shared why for some patients, the community oncology clinic is the only way to gain access to these life-saving treatments.

Both guests offer practical advice for bringing bispecifics to the community to help fellow physicians, and ultimately, patients.

Reference

Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. JADPRO. Published online September 11, 2024. https://doi.org/10.6004/jadpro.2024.15.8.15

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify